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Alzheimer’s disease (AD) is associated with the intra-
cellular aggregation of hyperphosphorylated tau and
the accumulation of b-amyloid in the neocortex. We
use transgenic mice harboring human tau (rTg4510)
and amyloid precursor protein (J20) mutations to
investigate transcriptional changes associated with
the progression of tau and amyloid pathology.
rTg4510 mice are characterized by widespread
transcriptional differences in the entorhinal cortex
with changes paralleling neuropathological burden
across multiple brain regions. Differentially ex-
pressed transcripts overlap with genes identified in
genetic studies of familial and sporadic AD. Sys-
tems-level analyses identify discrete co-expression
networks associated with the progressive accumula-
tion of tau that are enriched for genes and pathways
previously implicated in AD pathology and overlap
with co-expression networks identified in human
AD cortex. Our data provide further evidence for an
immune-response component in the accumulation
of tau and reveal molecular pathways associated
with the progression of AD neuropathology.
INTRODUCTION
Alzheimer’s disease (AD) is a chronic neurodegenerative disor-
der that is characterized by progressive neuropathology and
associated cognitive and functional decline (Scheltens et al.,
2016). In addition to the loss of synapses and neurons (manifest-
ing as brain atrophy), AD involves two neuropathological hall-
marks: (1) the formation of neurofibrillary tangles (NFTs) that
result from the intracellular aggregation of hyperphosphorylated
tau protein, also a characteristic of other neurodegenerative dis-
orders including frontotemporal dementia (FTD), and (2) the
development of amyloid plaques, which are extracellular de-
posits composed mainly of b-amyloid (Ab) protein that have
been the focus of extensive efforts in drug discovery. Although
these neuropathological signatures of AD have been relatively
well described in post-mortem human brain tissue, their exact2040 Cell Reports 30, 2040–2054, February 11, 2020 ª 2020 The Aut
This is an open access article under the CC BY license (http://creativemechanistic role in disease onset and progression remains
poorly understood (De Strooper and Karran, 2016). There have
been considerable advances in identifying the genetic risk fac-
tors for both familial and sporadic forms of AD; in addition to
the autosomal-dominant mutations in APP, PSEN1, and
PSEN2 that cause early-onset familial AD (Guerreiro et al.,
2012), the power of genome-wide association studies (GWAS)
and exome sequencing in large sample cohorts (Cruchaga
et al., 2014; Guerreiro et al., 2013; Hollingworth et al., 2011; Jan-
sen et al., 2019; Jonsson et al., 2013; Lambert et al., 2013; Sims
et al., 2017) has been used to identify both common and rare var-
iants associated with late-onset AD. Although the mechanisms
by which associated variants mediate disease susceptibility
are not well understood, many of the variants are non-coding
and hypothesized to involve regulatory disruption to transcrip-
tional networks across affected brain regions.
Mouse models of tau and amyloid have played a major role in
defining critical pathology-related processes, including facili-
tating our understanding of the brain’s transcriptional response
to the production and gradual deposition of tau and amyloid
into tangles and plaques (Go¨tz and Ittner, 2008). Recent studies
have identified widespread gene expression differences in trans-
genic (TG) mice harboring a diverse range of AD-associated mu-
tations (Castillo et al., 2017; Landel et al., 2014; Matarin et al.,
2015; Rothman et al., 2018; Swarup et al., 2019; Wes et al.,
2014; Neuner et al., 2019). However, most analyses to date
have been undertaken on relatively small numbers of animals
and have not attempted to directly relate transcriptional alter-
ations to the progressive burden of pathology frommultiple brain
regions in the same mice.
In this study, we systematically assess transcriptional signa-
tures associated with the progression of AD pathology in the
mouse brain, using highly parallel RNA sequencing (RNA-seq)
to quantify gene expression changes in the entorhinal cortex, a
region defined by primary and early neuropathology in human
AD (Braak and Braak, 1991). We used well-characterized TG
mouse models of both tau and amyloid pathology, collecting
transcriptional data at multiple time points carefully selected to
span from early to late stages of neuropathology in each model
(see Figure S1). First, to investigate transcriptional signatures
of progressive tau pathology, we used the rTg4510 mouse
model, which overexpresses a human mutant (P301L) form of
the microtubule-associated protein tau (MAPT) (Ramsdenhor(s).
commons.org/licenses/by/4.0/).
et al., 2005; Santacruz et al., 2005). Second, to investigate amy-
loid pathology, we used the J20 mouse line, which expresses a
mutant (K670N/M671L and V717F) form of the human amyloid
precursor protein (APP) (Hsia et al., 1999; Mucke et al., 2000).
Specific differentially expressed genes were validated using
qPCR and subsequently tested in the hippocampus, another
brain region affected by early pathology. Transcriptional profiles
were related to detailed neuropathological measurements of tau
and amyloid burden in the same mice, enabling us to directly
relate expression changes to the progressive accumulation of
neuropathology. We identified robust genotype-associated dif-
ferences in entorhinal cortex gene expression in both models
and widespread transcriptional changes paralleling the develop-
ment of tau pathology in rTg4510 mice. Systems-level analyses
uncovered discrete co-expression networks associated with the
progression of tau pathology that were enriched for genes and
pathways implicated in the onset of AD. Finally, we compared
these networks with those identified in AD patients, finding
considerable overlap with disease-associated co-expression
modules identified in the human cortex.
RESULTS
TG Mice with APP and MAPT Mutations Are
Characterized by Progressive Neuropathology
In both models, right brain hemisphere tissue sections from TG
and wild-type (WT) littermate control female mice (STAR
Methods) were used to quantify the progression of neuropa-
thology across multiple brain regions (Figures S2A and S2N).
First, in rTg4510 mice we measured levels of phosphorylated
tau at 2, 4, 6, and 8 months, comparing them with WT controls
at the same ages (n = 7–10 animals per group, total n = 74).
We identified a dramatic accumulation of tau pathology
in both the hippocampus (factorial ANOVA, F[3, 66] = 69.76,
p = 1.96E20) and entorhinal cortex (factorial ANOVA, F
[3, 51] = 9.86, p = 3.10E5) (Figures 1A–1C). Highly significant in-
creases in phosphorylated tau were also observed within spe-
cific sub-regions of the hippocampus and each of the additional
cortical regions we quantified (Figures S2B–S2M). Previous
studies have shown that rTg4510 mice develop pretangles
around 2.5 months of age, with NFT pathology starting in the
neocortex and progressing rapidly into the hippocampus and
limbic structures with increasing age (Ramsden et al., 2005;
Sahara et al., 2014; Santacruz et al., 2005). The spread of tau pa-
thology in rTg4510 mice therefore reflects the spread of NFTs
with increasing Braak stage in AD (Braak and Braak, 1991). Sec-
ond, we quantified levels of amyloid pathology in J20 mice at
ages 6, 8, 10, and 12 months, comparing them with WT controls
at the same ages (n = 9 or 10 animals per group, total n = 73). We
again identified dramatic increases in pathology in the hippo-
campus (factorial ANOVA, F[3, 68] = 66.85, p = 3.00E20),
with a more modest increase in the entorhinal cortex (factorial
ANOVA, F[3, 53] = 6.42, p = 0.00086) (Figures 1D–1F), and a sig-
nificant accumulation of amyloid was also observed in each of
the other cortical regions examined (Figures S2O–S2R). To our
knowledge, no previous study has quantified amyloid progres-
sion in entorhinal cortex in J20 mice, and it is noteworthy that
we observe lower levels of pathology in this region comparedwith the hippocampus and other neocortical regions. Our results
concur with previous data highlighting progressive deposition of
amyloid plaques in the hippocampus and neocortex of J20 mice
at 5–7 months and ubiquitous plaque pathology by 8–10 months
of age (Harris et al., 2010a;Mucke et al., 2000), reflecting the pro-
gressive deposition of amyloid seen in individuals with AD (Thal
et al., 2002). Finally, we quantified neuropathology in the thal-
amus from both models, which, as expected, showed markedly
lower levels of tau (rTg4150; Figure S2M) and amyloid (J20; Fig-
ure S2R) pathology relative to the other brain regions tested.
The rTg4510 Model of Tau Pathology Is Characterized
by Widespread Transcriptional Differences in the
Entorhinal Cortex
The entorhinal cortex was dissected from the left hemisphere of
the brain from each individual mouse (TG and WT) at each of the
four time points. High-quality RNA (mean RNA integrity number
[RIN] rTg4510 = 8.9 [SD = 0.2], mean RIN J20 = 8.6 [SD = 0.3])
was isolated from each sample (total n = 121) and used for highly
parallel RNA-seq (STAR Methods). After stringent quality
control (QC) of the raw RNA-seq data (STAR Methods), we
obtained a mean of 18.18 million (SD = 3.33 million) sequencing
reads per sample for the rTg4510 dataset and a mean of
22.05 million (SD = 2.88 million) sequencing reads per sample
for the J20 dataset (Table S1), with no difference in read
depth between TG and WT controls (rTg4510: two-tailed
unpaired t test, t[57] = 1.35, p = 0.18; J20: two-tailed unpaired
t test, t[60] = 0.41, p = 0.18). We quantified read counts for
each transcript and evaluated differences in gene expression be-
tween TG and WT animals for each model (STAR Methods). Our
extensive gene expression dataset generated on rodent models
of AD pathology is well powered to identify transcriptional
variation associated with mutations in MAPT and APP and the
progressive changes in gene expression accompanying the
development of AD pathology in TG mice (Figure S1C).
Across all samples, extensive differences in gene expression
were identified in rTg4510 TG animals relative to WT control
mice (n = 29 TG, n = 30 WT); gene expression results for all
18,822 detected transcripts are available for download (STAR
Methods). In total we identified 154 differentially expressed
transcripts at a stringent false discovery rate (FDR) of <0.05
(Figure 2A; Table S2). Among these, there was a significant
(exact binomial test, n = 154 transcripts, p = 0.00014) enrichment
of downregulated transcripts (n = 101 transcripts [66%] with
reduced expression in TG compared with n = 53 transcripts
[34%] with elevated expression in TG). Of note, differences for
five of these transcripts are likely to reflect known deletions of
the transgene integration sites for the CaMKIIa-tTA (encompass-
ingWdr60, Esyt2, Ncapg2, and Ptprn2) and MAPT (encompass-
ing Fgf14) transgenes (Goodwin et al., 2017; Gamache et al.,
2019). Given the high homology between transcribed regions
of the human and mouse tau gene, we also find elevated
levels of Mapt (Wald statistic = 11.11, log2 fold change = 0.50,
FDR = 7.08E25) (Figure S3A), confirming stable activation of
the MAPT transgene in TG mice; of note, human-specific
MAPT sequence domains were detected only in TG mice
(Figures S3B and S3C). Furthermore, because the rTg4510
transgene is inserted into the context of two untranslated exonsCell Reports 30, 2040–2054, February 11, 2020 2041
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Figure 1. Transgenic Models Expressing Mutant Human MAPT and APP Exhibit Progressive Neuropathology
(A) Representative immunohistochemistry images from the hippocampus (CA1) showing accumulation of tau pathology in rTg4510 transgenic (TG) mice
compared with wild-type (WT) control mice at 2, 4, 6, and 8 months of age.
(B) There was a progressive increase in hippocampal tau in rTg4510 TG but not WT animals (total n = 73 animals; 8–10 animals per group; factorial
ANOVA, F[3, 66] = 69.76, p = 1.96E20).
(C) There was a progressive increase in tau in the entorhinal cortex in rTg4510 TG but not WT animals (total n = 59 animals; 6–8 animals per group; factorial
ANOVA, F[3, 51] = 9.86, p = 3.10E5).
(D) Representative immunohistochemistry images from the hippocampus showing progressive accumulation of amyloid pathology in J20 TGmice comparedwith
WT mice at 6, 8, 10, and 12 months of age.
(E) There was a progressive increase in hippocampal amyloid in J20 TG but not WT mice (total n = 77 animals; 9 or 10 animals per group; factorial ANOVA,
F[3, 68] = 66.85, p = 3.00E20).
(F) There was a modest increase in amyloid in the entorhinal cortex of J20 TG but not WT mice, particularly in later stages (total n = 62 animals; 7 or 8 animals per
group; factorial ANOVA, F[3, 53] = 6.42, p = 0.00086).
Dashed lines represent mean paths of pathological burden across the four age groups.of the mouse prion protein gene (Prnp), as expected we observe
elevated expression of these Prnp domains in TG mice (Wald
statistic = 25.40, log2 fold change = 1.54, FDR = 4.88E138).
Beyond these expected direct transgene-induced changes,
we observed evidence for widespread transcriptional conse-
quences of the rTg4510 genotype (Table S2). Themost significant
rTg4510-associated differentially expressed transcript is Car4,
which encodes carbonic anhydrase 4 (upregulated in TG
mice; Wald statistic = 8.36, log2 fold change = 1.11, FDR =
2.41E13). Other differentially expressed genes in mice
carrying the rTg4510 transgene include Gpr17, which encodes
G protein-coupled receptor 17, which is involved in regulating
oligodendrocyte differentiation and maturation (Chen et al.,2042 Cell Reports 30, 2040–2054, February 11, 20202009) (downregulated in TG mice; Wald statistic = 6.73, log2
fold change = 0.62, FDR = 5.11E08); Blnk, which encodes a
cytoplasmic linker protein that plays a critical role in B cell devel-
opment and is involved in the TREM2 activation pathway (Zajko-
wicz et al., 2018) (upregulated in TG mice; Wald statistic = 6.48,
log2 fold change = 0.80, FDR = 2.12E07); and Hspa5 (also
known as Bip or Grp78), which encodes a member of the heat
shock protein 70 (HSP70) family that is localized in the lumen of
the endoplasmic reticulum (ER) and involved in the folding and
assembly of proteins and has been previously implicated in neu-
roprotection and AD (Casas, 2017; Hoozemans et al., 2005)
(downregulated in TG mice; Wald statistic = 6.16, log2 fold
change = 0.58, FDR = 1.37E06). Hierarchical clustering of
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individual mice on the basis of expression levels for genotype-
associated transcripts robustly discriminates between rTg4510
and WT groups (Figure 2A). Within the rTg4510 TG group, sam-
ples also cluster by time point, suggesting, importantly, that there
are progressive changes in gene expression within the mutant
mice and highlighting the value of performing longitudinal
analyses. Finally, using qPCR, we validated top-ranked geno-
type-associated expression differences in the entorhinal cortex
(Figure S4; Table S3) and found parallel dysregulation of these
genes in matched hippocampus samples dissected from the
same individuals (Car4: t test statistic = 29.05, FDR =
4.90E32; Gpr17: t test statistic = 2.19, FDR = 0.035; Blnk:
t test statistic =18.13, FDR = 3.98E23;Hspa5: t test statistic =
4.14, FDR = 0.00019) (Figure S4; Table S3).The J20 Model of Amyloid Pathology Is Characterized
by Differential Expression of Ccdc80, Abca8a, Htr1a,
and Hspa5
Relative to the widespread transcriptional signatures associated
with the rTg4510model, fewer significant expression differences
were identified in J20 TG mice compared with WT control mice
(n = 30 TG, n = 32WT); gene expression results for all 18,745 ex-
pressed transcripts are available for download (STAR Methods).
As expected, there was an apparent upregulation of App (Wald
statistic = 8.55, log2 fold change = 0.66, FDR = 2.37E13) (Fig-
ure S3D), reflecting the high sequence homology with the human
APP transgene and confirming stable activation of the mutant
transgene in TG mice; of note, we mapped our RNA-seq reads
to human-specific APP sequence domains and observed signal
only in TG animals (Figures S3E and S3F). In total we identified
four additional differentially expressed transcripts at FDR <
0.05 (Figure 2B; Table S2): Ccdc80, encoding a protein involved
in cell adhesion and matrix assembly (O’Leary et al., 2013)
(upregulated in TG samples; Wald statistic = 6.37, log2 fold
change = 0.81, FDR = 1.74E06); Abca8a, encoding a member
of the A-subclass of ATP-binding cassette (ABC) transporter
family that regulates brain lipid homeostasis and has been impli-
cated in AD (Piehler et al., 2012) (downregulated in TG samples;
Wald statistic = 4.67, log2 fold change = 0.81, FDR = 0.02);
Htr1a, encoding a major G protein-coupled serotonin receptor,
the 5-HT1A receptor, which is widely expressed in the central
nervous system (CNS) (downregulated in TG samples; Wald sta-
tistic = 4.48, log2 fold change = 0.51, FDR = 0.035); and
Hspa5 (downregulated in TG samples, Wald statistic = 4.36,
log2 fold change = 0.28, FDR = 0.049). Overall, expression of
these genotype-associated transcripts discriminates between
J20 and WT groups (Figure 2B), although, in contrast to the
rTg5410 differentially expressed transcripts, there are no clear
age effects in the J20 TG mice. Although the transcriptional
changes associated with the rTg4510 and J20 genotypes areFigure 2. Genotype-Associated Transcriptional Variation Robustly Dis
Normalized DESeq2 read counts, relative to mean levels of expression across all
(blue).
(A) Hierarchical clustering of individual mice on the basis of expression levels for
[29 TG, 30 WT], 147 transcripts).
(B) Hierarchical clustering of individual mice on the basis of expression levels for di
32 WT], 5 transcripts).
2044 Cell Reports 30, 2040–2054, February 11, 2020generally distinct—there is no robust correlation of effect sizes
(TG versusWT) betweenmodels for differentially expressed tran-
scripts identified in either the rTg4510 (Pearson correlation, r =
0.15, p = 0.063; Figure S5A) or J20 (r = 0.66, p = 0.23; Figure S5B)
models—it is noteworthy that Hspa5 is significantly downregu-
lated (FDR < 0.05) in the entorhinal cortex in the same direction
in both models, implicating a role for ER stress in both tau and
amyloid pathology. Of note, recent evidence suggests that acti-
vation of this gene is essential for the initiation of the unfolded
protein response (UPR) in Parkinson’s disease (Enogieru et al.,
2019). Finally, using qPCR we confirmed differential expression
in the entorhinal cortex and found parallel dysregulation of
two of the J20-associated transcripts in the hippocampus
dissected from the same individuals (Abca8a: t test statistic =
2.74, FDR = 0.015; Ccdc80: t test statistic = 8.57, FDR =
7.60E11) (Figures S4I–S4L; Table S3).Progressive Changes in Gene Expression Mirror the
Development of Neuropathology in the rTg4510 Model
of Tau Pathology
Given the progressive accumulation of brain neuropathology
in TG mice (Figure 1), we next explored temporal changes in
gene expression associated with genotype to identify transcrip-
tional signatures paralleling the increases in tau and amyloid pa-
thology in TGmice over time (Figure S1C).We initially focused on
the rTg4510 mice given the clear temporal clustering of samples
among genotype-associated differentially expressed transcripts
identified in this model (Figure 2A). First, using an approach de-
signed to identify interactions between genotype (TG versusWT)
and age group, we identified 1,762 transcripts (FDR < 0.05)
whose expression significantly changed with time in TG
rTg4510 mice (Table S4). The top progressively altered gene in
rTg4510 TGmicewasGfap, encoding glial fibrillary acidic protein
(GFAP), a gene predominantly expressed in both mouse and hu-
man astrocytes (Raff et al., 1979; Zhang et al., 2016) and known
to be upregulated in reactive astrocytes associated with brain
pathology (Ben Haim et al., 2015). GFAP is extremely sensitive
to changes in the homeostasis of the brain and responds early
in the course of neurodegenerative disease (Sofroniew, 2009).
We found that Gfap was dramatically upregulated across age
groups (Figure 3A; likelihood ratio test [LRT] statistic =
106.321, FDR = 1.28E18), similar to results from another study
reporting age-dependent (12–18 months) upregulation of hippo-
campal Gfap in tau (CaMKII-MAPT P301L) and amyloid (APP/
PSEN1) mouse models (Matarin et al., 2015) and paralleling the
astrogliosis observed in human AD brain (Liddelow et al., 2017;
Panter et al., 1985). Other top-ranked genes progressively
altered in rTg4510 mice were notably enriched for microglial
markers previously shown to be upregulated in AD (Hopperton
et al., 2018; Keren-Shaul et al., 2017), includingCd68 (Figure 3B;criminates between Transgenic and Wild-Type Mice
individual mice, are represented in the heatmaps (scaled) from high (red) to low
differentially expressed genes associated with rTg4510 genotype (n = 59 mice
fferentially expressed genes associated with J20 genotype (n = 62mice [30 TG,
A B C D
E F G H
Figure 3. Top-Ranked Progressively Differentially Expressed Genes in rTg4510 Mice
Top row shows normalized RNA-seq read counts for entorhinal cortex. Bottom row shows targeted qPCR data for the same genes in matched hippocampus
tissue. Dashed lines represent mean paths for each time point.
(A) Gfap (LRT statistic = 106.32, log2 fold change [2–8 months] = 2.75, FDR = 1.28E18).
(B) Cd68 (LRT statistic = 103.77, log2 fold change [2–8 months] = 1.85, FDR = 2.26E18).
(C) Itgax (LRT statistic = 86.85, log2 fold change [2–8 months] = 4.42, FDR = 6.54E15).
(D) Clec7a (LRT statistic = 83.20, log2 fold change [2–8 months] = 5.37, FDR = 2.97E14).
(E) Gfap (interaction F statistic = 36.93, FDR = 3.69E11).
(F) Cd68 (interaction F statistic = 30.86, FDR = 3.33E10).
(G) Itgax (interaction F statistic = 12.94, FDR = 9.80E6).
(H) Clec7a (interaction F statistic = 3.74, FDR = 0.034).LRT statistic = 103.77, FDR = 2.26E18), Itgax (or Cd11c) (Fig-
ure 3C; LRT statistic = 86.85, FDR = 6.54E15), andClec7a (Fig-
ure 3D; LRT statistic = 83.20, FDR = 2.97E14). These genes
have been previously reported to be upregulated in hippocampal
tissue from 6-month-old rTg4510 female mice (Wes et al., 2014),
in isolatedmicroglia from rTg4510mice (Wang et al., 2018), in the
cortex of amyloid mice at late stages of pathology (Rothmanet al., 2018), and in the neocortex, hippocampus, and microglia
of micewith amyloid and tau pathology (Keren-Shaul et al., 2017;
Landel et al., 2014). Of note, the list of transcripts progressively
altered in rTg4510 mice also includes genes robustly associated
with familial AD from genetic studies of human patients,
including App (Figure S6A; LRT statistic = 13.88, FDR = 0.037),
a key driver of amyloid pathology, and genes annotated toCell Reports 30, 2040–2054, February 11, 2020 2045
A B C
Figure 4. Transcriptional Variation Associated with Levels of Tau Pathology in rTg4510 Entorhinal Cortex
(A) Association statistics for transcripts differentially expressed with age in rTg4510 TG mice were highly correlated with those from analyses of tau pathology in
the entorhinal cortex (r = 0.70, p < 1E200).
(B and C) There was a notable overlap in top-ranked genes, including (B) Gfap (r = 0.89, p = 4.60E20) and (C) Itgax (r = 0.80, p = 1.41E13).both common and rare variants identified in GWAS and exome-
sequencing studies of late-onset sporadic AD (LOAD), including
Trem2 (LRT statistic = 43.82, FDR = 3.73E07), Pld3 (LRT statis-
tic = 36.80, FDR = 5.80E06), Frmd4a (LRT statistic = 27.81,
FDR = 0.00022), Clu (LRT statistic = 27.73, FDR = 0.00023),
Apoe (LRT statistic = 22.99, FDR = 0.0014), Picalm (LRT statis-
tic = 21.37, FDR = 0.0025), Cd33 (LRT statistic = 27.32, FDR =
0.00026), and Abi3 (LRT statistic = 17.10, FDR = 0.012) (Figures
S6B–S6I).
Given that there is some variability in gene expression and tau
pathology within each of the four TG age groups, we next related
RNA-seq to immunohistochemistry data (STAR Methods) to
identify transcripts whose expression is significantly associated
with actual levels of tau quantified in the entorhinal cortex and
hippocampus (Table S5) from in the same individual mice. As ex-
pected, association statistics for transcripts differentially ex-
pressed with age in TG mice were highly correlated with those
from analyses of tau pathology in both brain regions (entorhinal
cortex: r = 0.70, p < 1E200 [Figure 4A]; hippocampus: r =
0.58, p = 1.8E149 [Figure S5D]), with a notable overlap in
top-ranked genes including Gfap (Wald statistic = 16.97,
FDR = 1.32E60; Figure 4B) and Itgax (Wald statistic = 16.01,
FDR = 6.89E54; Figure 4C). We used qPCR to (1) validate
top-ranked temporal and pathology-associated changes in
Gfap, Cd68, Itgax, and Clec7a expression; (2) confirm changes
in levels of selected genes also implicated by genetic studies
of AD (Apoe, Cd33, Clu, Frmd4a, Picalm, Pld3, and Trem2)
(FDR < 0.05 for all; Table S3); and (3) identify parallel
changes in the expression of the majority of these genes in
the hippocampus from the same individual mice (Gfap: inter-
action F statistic = 36.93, FDR = 3.69E11; Cd68: interaction
F statistic = 30.86, FDR = 3.33E10; Itgax: interaction
F statistic = 12.94, FDR = 9.80E6; Clec7a: interaction F statis-
tic = 3.74, FDR = 0.034) (Figures 3E–3H; Table S3).
Overall, the progression of tau pathology is associated with
the downregulation of key neuronal markers, with an upregula-
tion of transcripts associated with astrocytes and microglia
(Figure S7). We usedGOseq (STARMethods) to identify ontolog-
ical enrichments among genes characterized by progressively2046 Cell Reports 30, 2040–2054, February 11, 2020altered gene expression in rTg4510 mice, finding highly signifi-
cant enrichments for immune related biological pathways
including ‘‘immune system process’’ (FDR = 1.03E25),
‘‘defence response’’ (FDR= 2.98E24), and ‘‘immune response’’
(FDR = 4.79E24) (Table S6). Given these findings, we next
quantified Iba1, a microglia/macrophage-specific calcium-
binding protein (Ohsawa et al., 2004), in matched tissue sections
from the right brain hemisphere (n = 7–10 animals per group,
total n = 70), observing a significant increase in all brain regions
(hippocampus: factorial ANOVA, F[3, 62] = 12.60, p = 1.56E06;
cortex: factorial ANOVA, F[3, 62] = 18.13, p = 1.47E08;
thalamus: factorial ANOVA, F[3, 62] = 18.85, p = 8.37E09)
(Figures S2K–S2M). Together our results reflect the dramatic
upregulation of microglial genes observed in studies of other
AD rodent models (Kamphuis et al., 2016; Kan et al., 2015;
Keren-Shaul et al., 2017; Landel et al., 2014; Matarin et al.,
2015; Rothman et al., 2018), and support a role, either causal
or consequential, for dysregulation of the CNS immune pro-
cesses in the development of AD pathology. Of note, recent tran-
scriptional studies in human brain have shown that microglial
gene networks are upregulated in response to AD neuropa-
thology (Felsky et al., 2019).
In Contrast to the Dramatic and Progressive
Transcriptional Changes Identified in rTg4510 Mice,
Relatively Few Changes Were Associated with the
Development of Pathology in J20 Mice
In total we identified five transcripts (Cst7,Wdfy1, Grxcr2, Itgax,
and Ifitm1) whose expression profiles significantly changed
(FDR < 0.05) with age in TG J20mice (Table S4). Using our immu-
nohistochemistry data, we identified 11 transcripts significantly
associated with levels of amyloid pathology in the entorhinal cor-
tex and 223 associated with hippocampal pathology (Table S5).
Although pathology association statistics for common differen-
tially expressed genes were highly correlated across both brain
regions (Pearson correlation, r = 0.87, p = 0.0011), the higher
number of associations identified for the hippocampus likely re-
flects the more abundant pathology observed in this brain region
in TG mice (Figures 1E and 1F). The relatively small overall
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Figure 5. Effect Sizes for Differentially
Expressed Transcripts Associated with
Progression of Tau in rTg4510 Mice Are
Correlated with Those Observed with Pro-
gression of Amyloid in J20 Mice
(A) Positive correlation for effect size (log2 fold
change from latest time point compared with
baseline) for significant transcripts in rTg4510
mice (r = 0.46, p = 1.50E92; exact binomial test,
n = 1,762 transcripts, p = 1.97E05).
(B) Two transcripts (Cst7 and Itgax) were signifi-
cantly associated with the progression of both
tau (rTg4510) and amyloid (J20) pathology (r = 0.77,
p = 0.13; exact binomial test, n = 5 transcripts,
p = 0.13).
(C) Cst7 gene expression in rTg4510 mice (total
n = 59 animals, 6–8 animals per group, LRT sta-
tistic = 36.10, log2 fold change [2–8months] = 6.59,
FDR = 7.71E06). rTg4510 transgenic (TG) female
mice compared with wild-type (WT) littermate
control mice.
(D) Cst7 gene expression in the J20 mice (total
n = 62 animals, 6–8 animals per group, LRT sta-
tistic = 37.37, log2 fold change [6–12 months] =
2.42, FDR = 0.00072).
J20 transgenic (TG) female mice compared with
wild-type (WT) littermate control mice. Itgax gene
expression in rTg4510 and J20 mice is shown in
Figure 3C and Figure S8, respectively.number of significantly altered genes in J20 mice potentially re-
flects the slower and later accumulation of pathology in these
mice compared with rTg4510 mice. Previous work has also
shown relatively limited amyloid pathology in J20 entorhinal cor-
tex even at 14 months of age (Harris et al., 2010b), with neuronal
cell loss varying by brain region (Wright et al., 2013). Neverthe-
less, we found that effect sizes for the transcripts identified as
being progressively dysregulated in rTg4510 and in J20 mice
were significantly correlated across both models, suggesting
some common molecular signals associated with both tau and
amyloid pathology (Figure 5). Interestingly, two genes (Cst7
and Itgax) identified as being associated with progressive tau pa-
thology in rTg4510 mice were also significantly associated with
amyloid pathology in J20 mice (Figure 5; Figure S8). Like Itgax,
Cst7 has been shown to be a marker for activated microgliaCell Repoand upregulated in AD pathology (Keren-
Shaul et al., 2017; Ofengeim et al.,
2017); of note, Cst7 was previously re-
ported to be the top upregulated gene in
cortex samples from 12-month-old APP
NL-G-F knockin mice (Castillo et al.,
2017). Finally, we used qPCR to confirm
significant temporal and pathology-asso-
ciated changes in expression of Cst7 and
Itgax in the J20 entorhinal cortex (Table
S3) and identified parallel changes in the
hippocampus from the same individuals
(Cst7: interaction F statistic = 48.16,
FDR = 3.76E13; Itgax: interaction F sta-
tistic = 13.09, FDR = 1.31E5) (Table S3).Of note, the changes identified in the hippocampus for these
genes were considerably larger than those in the entorhinal cor-
tex, further reflecting the higher hippocampal levels of amyloid
pathology.
Transcriptional Changes Identified in rTg4510 Mice
Reflect Those Observed in Other Models of Tau
Pathology
A number of recent studies have also described evidence for
differential gene expression in TG models of familial AD
gene mutations (Castillo et al., 2017; Keren-Shaul et al.,
2017; Landel et al., 2014; Matarin et al., 2015; Rothman et al.,
2018; Wang et al., 2018; Wes et al., 2014). We therefore
explored hippocampal RNA-seq data from two other
TG models (TAU [CaMKII-MAPTP301L] and TAS10 [SwAPP,rts 30, 2040–2054, February 11, 2020 2047
K670N/M671L]) (Matarin et al., 2015; Salih et al., 2019) to identify
consistencies in the transcriptional signatures between different
models of tau and amyloid pathology (STAR Methods; http://
www.mouseac.org). Effect sizes for rTg4510 genotype-associ-
ated transcripts also present in the Mouseac TAU RNA-seq da-
taset (n = 138) were significantly correlated between the two
models (Pearson correlation, r = 0.33, p = 7.7E05). Despite
this consistency in effect sizes, many of the differentially ex-
pressed genes associated with rTg4510 genotype were not sta-
tistically replicated in the TAU model (Figure S5C; Table S7),
although this likely reflects the distinct genetic background of
the different TG lines and the modest power to detect effects
given the small number of samples from the Mouseac dataset
(n = 49 RNA-seq samples, one to four animals per age group, af-
ter filtering for samples with complete phenotypic data). As ex-
pected, given the limited evidence for consistency in genotype
effects between rTg4510 and J20 mice, there was no correlation
between effects observed in rTg4510 and TAS10 mice for the
145 rTg4510-associated genes present in both datasets. In
contrast, association statistics for the 1,640 transcripts identified
as being progressively altered with age in rTg4510 mice and also
present in the Mouseac datasets (Table S7) were significantly
correlated with those for the same genes in both TAU (r = 0.46,
p = 1.2E86) and TAS10 (r = 0.23, p = 3.9E21) TGmice (Figures
S5E and S5F). Given the small number of progressive alterations
observed in J20 mice, it was not possible to systematically
explore overlaps between differentially regulated genes in this
model and the two Mouseac models. Of note, however, the
two genes identified as being temporally altered in both
rTg4510 and J20 mice, Cst7 and Itgax, were both similarly
altered in both the TAU and TAS10 models (Figure S8).
Gene Co-expression Networks Associated with the
Progression of Tau Pathology Are Enriched for
Functional Pathways Related to Synaptic Transmission,
the Immune System, and Glial Cell Activation
Given the dramatic transcriptional changes identified in rTg4510
mice, we next used weighted gene correlation network analysis
(WGCNA) (STAR Methods) to identify discrete co-expression
modules and describe systems-level transcriptional variation
associated with rTg4510 genotype and progression of tau pa-
thology. We constructed co-expression networks using entorhi-
nal cortex RNA-seq data from rTg4510 TG and WT mice (n = 58
mice), identifying 18 discrete co-expressionmodules (Figure S9).
Next, we used a linear regression model (STAR Methods) and
identified six co-expression modules (here named ‘‘salmon,’’
‘‘turquoise,’’ ‘‘purple,’’ ‘‘yellow,’’ ‘‘light-cyan,’’ and ‘‘red’’) that
were significantly (Bonferroni-corrected p < 0.0028) associated
with rTg4510 genotype (Figures S9A and S9B; Table S8). These
tau-associated co-expression modules are highly enriched for
molecular functions and biological pathways directly related to
AD: the red module, which was downregulated in TG mice
compared with WT mice (b = 0.18, p = 1.43E10), is highly en-
riched for functional pathways involved in synaptic transmission;
the turquoise module, which was upregulated in TG mice
compared with WT mice (b = 0.18, p = 3.04E10), is enriched
for pathways involved in activation of the immune system; the
salmon module, which was consistently upregulated in TG2048 Cell Reports 30, 2040–2054, February 11, 2020mice compared with WT mice (b = 0.14, p = 3.58E06), is en-
riched for genes involved in myelination and glial cell activation;
the purple module, which was downregulated in TG mice
compared with WT mice (b = 0.13, p = 0.00012), is enriched
for pathways related to cellular component disassembly; and
the yellow module, which was downregulated in TG mice
compared with WT mice (b = 0.10, p = 0.0015), is enriched
for pathways related to mitochondria and synaptic processes
(Table S6). The module eigengenes for three of these co-expres-
sion modules (turquoise, yellow, and red) exhibited a significant
interaction between genotype and age in rTg4510 mice
(Figure S9A; Table S8), suggesting that they are temporally
linked to the development of tau pathology in TG mice (Figures
6A–6C). The turquoise module becomes increasingly upregu-
lated with time in TG mice (b = 0.28, p = 4.23E06), the red
module becomes increasingly downregulated with time in TG
mice (b = 0.21, p = 0.0022), and the yellow module becomes
downregulated specifically during the later time points in TG
mice (b = 0.29, p = 0.0018). Using the matched immunohisto-
chemistry data generated across multiple brain regions for
each mouse, we were able to explore the relationship between
co-expression modules and actual tau pathology in rTg4510
mice, confirming that the turquoise, yellow, and red modules
are robustly associated with the accumulation of tau across
the brain (Figure S9C). The association with pathology was
particularly strong in highly affected brain regions, including
the entorhinal cortex (Figures 6D–6F) and hippocampus
(Figure S10); in both regions the module eigengene for the tur-
quoise module is positively correlated with levels of tau in TG
mice (hippocampus: r = 0.85, p = 1.20E16; entorhinal cortex:
r = 0.82, p = 4.00E15), and those for the yellow (hippocampus:
r = 0.63, p = 2.00E07; entorhinal cortex: r = 0.50, p =
7.52E5) and red (hippocampus: r =0.79, p = 4.61E13; ento-
rhinal cortex: r = 0.75, p = 8.01E12) modules are negatively
correlated with levels of tau in TG mice. Although these co-
expression modules were also correlated with measures of tau
pathology in the thalamus, the magnitude of effects was much
lower, reflecting the later and less aggressive accumulation of
tau in this region of the brain (Figures S10J–S10L).
Within each of these three modules we ranked transcripts on
the basis of their intramodular connectivity to identify ‘‘hub’’
genes within each network, finding many genes known to play
a major role in the neuro-immunological and neurodegenerative
processes involved in AD. In the turquoisemodule the four genes
with the highest intramodular connectivity (i.e., those with most
connections to other genes) were Cd63, Msn, Npc2, and
Tnfrsf1a (Table S9), with other highly interconnected transcripts
including several genes identified as having a role in LOAD from
GWAS (e.g., Abca1, Clu, and Apoe) in addition to genes previ-
ously implicated in AD pathology (e.g., Itgax, Clec7a, and
Cd68). Furthermore, genes identified as having the strongest
connections (edges) to other genes (nodes) in the turquoise
module included C1qb, Mpeg1, Tyrobp, and Trem2 (Figure 7A).
In the yellow module, the four transcripts with the highest intra-
modular connectivity were Atp9a, Ywhag, Rab3a, and Svop,
with App also being a highly connected gene in this module
(Table S9); genes identified as having the strongest connections
to other genes included Atp9a, Faim2, and Ppp2r1a (Figure 7B).
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Figure 6. Variation in Entorhinal Cortex Co-expression Modules Parallels the Accumulation of Tau Pathology in rTg4510 Mice
(A–C) Shown are module eigengene values for individual mice at four time-points for (A) the turquoise module (n = 3,091 transcripts; linear regression, F[3, 50] =
12.18, b = 0.28, p = 4.23E06); (B) the yellow module (n = 1,102 transcripts; linear regression, F[3, 50] = 5.79, b = 0.29, p = 0.0018); and (C) the red module
(n = 726 transcripts; linear regression, F[3, 50] = 5.58, b =0.21, p = 0.0022). The samemodules are correlated with tau pathology in entorhinal cortex in the same
individuals.
(D) Positive correlation between module eigengene in the turquoise module and tau pathology in the entorhinal cortex (Pearson correlation, r = 0.82,
p = 4.00E15).
(E) Negative correlation betweenmodule eigengene in the yellowmodule and tau pathology in the entorhinal cortex (Pearson correlation, r =0.50, p = 7.52E5).
(F) Negative correlation between module eigengene in the red module and tau pathology in the entorhinal cortex (Pearson correlation, r = 0.75, p = 8.01E12).
Total n = 58 animals (6–8 animals per group). Colored circles represent rTg4510 TG mice, and white circles represent WT control mice. Dashed lines represent
mean paths for each time point.In the redmodule,Atxn7l3,Sept5,Cbx6, and Fbxl16were the top
most connected genes (Table S9); genes with the strongest con-
nections to other genes in the red module included Dlgap3,
Shank3, Epn1, and Fbxl16 (Figure 7C).
Co-expression Changes Identified in rTg4510 Mice
Overlap with AD-Associated Co-expression Changes in
Human Brain
We next compared the significant rTg4510 co-expression mod-
ules with AD-associated co-expression modules reported in a
recent human post-mortem RNA-seq meta-analysis (Logsdon
et al., 2019), focusing on modules identified in dorsolateral pre-
frontal cortex (DLPFC) and temporal cortex (TCX). Briefly, we
used a hypergeometric test to identify overlaps between the
six rTg4510-associated co-expression modules (salmon, tur-
quoise, purple, yellow, light cyan, and red) and four DLPFC
and five TCX AD-associated human co-expression modules
(Table S10), restricting our analysis to mouse-human homologs
(STARMethods). After controlling for the number of comparisonsperformed for each of the human brain regions (DLPFC, p <
0.0021; TCX, p < 0.0017), each of the rTg4510-associated mod-
ules was found to significantly overlap with at least one AD-asso-
ciated module in both human cortical regions. For example,
genes in the turquoise rTg4510 module (enriched for pathways
involved in activation of the immune system; Table S6) were
found to overlap significantly with two human DLPFC modules
(‘‘DLPFC-blue’’ and ‘‘DLPFC-brown’’) and three TCX modules
(‘‘TCX-blue,’’ ‘‘TCX-turquoise,’’ and ‘‘TCX-yellow’’) associated
with AD from Logsdon et al. (2019); for this module, the largest
proportion of overlaps in genes were found with the ‘‘DLPFC-
blue’’ module (n = 658 genes, 40.82% of the human module
gene list, p < 2.2E16) and the ‘‘TCX-turquoise’’ module
(n = 389 genes, 39.1% of the human module gene list, p <
2.2E16). Interestingly, GOseq analysis highlighted a strong
enrichment for immune response processes among the
rTg4510 turquoise module genes overlapping with those in
both the ‘‘DLPFC-blue’’ module and the ‘‘TCX-turquoise’’ mod-
ule (Table S6). Reflecting the similarities between these twoCell Reports 30, 2040–2054, February 11, 2020 2049
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Figure 7. Network Plots Highlighting Core Members of Gene Co-
expression Modules Associated with the Development of Tau
Pathology
Shown are the top 50 nodes (i.e., genes) with the strongest edges (repre-
senting individual connections with other genes) for each module.
(A) Turquoise module (all upregulated genes).
(B) Yellowmodule (downregulated genes in yellow, upregulated genes in gray).
(C) Red module (all downregulated genes).
Stronger colors reflect higher absolute log2 fold change (8 months against
2 months). Total n = 58 animals (6–8 animals per group).
2050 Cell Reports 30, 2040–2054, February 11, 2020human cortex modules, the list of overlapping genes includes
many of the core hub transcripts identified in the rTg4510 tur-
quoise module for both the ‘‘DLPFC-blue’’ (e.g., CD63,
ABCA1, CLU, APOE, ITGAX, CLEC7A, C1QB, TYROBP, and
TREM2) and ‘‘TCX-turquoise’’ (e.g., CD63, ITGAX, CLEC7A,
C1QB, TYROBP, and TREM2) human modules. Together, these
results indicate that the transcriptional networks associated with
tau pathology in rTg4510 mice overlap considerably with those
identified in human AD cortex and are involved in driving com-
mon molecular pathways.
DISCUSSION
In this study, we identified transcriptional changes in the entorhi-
nal cortex associated with the progression of AD-associated
pathology in TG models of both tau (rTg4510) and amyloid
(J20) pathology. We found genotype-associated differences in
entorhinal cortex gene expression in both models and identified
widespread changes in gene expression paralleling the develop-
ment of tau pathology in rTg4510 mice and reflecting alterations
observed in other models of tau pathology. Specific findings
were subsequently validated using qPCR and also tested in
the hippocampus, with similar patterns observed across both
brain regions. Of note, the list of transcripts progressively altered
in rTg4510 mice includes genes robustly associated with familial
AD from genetic studies of human patients, including App which
is a key driver of amyloid pathology. It also includes genes anno-
tated to both common and rare variants identified in GWAS and
exome-sequencing studies of LOAD. Systems-level analyses
identified discrete co-expression networks associated with the
progressive accumulation of tau, with these also being enriched
for genes and pathways previously implicated in neuroimmune
and neurodegenerative processes driving AD pathology. Further
support for upregulation of immune system genes in response to
tau pathology comes from our finding of increased expression of
complement pathway genes including C1qa, C1qb, and C1qc.
Finally, we compared these tau-associated networks with
those identified in human post-mortem tissue from AD individ-
uals, finding considerable overlap with disease-associated co-
expression modules.
Our study represents a systematic analysis of transcriptional
variation in mouse models of tau and amyloid pathology,
focusing primarily on changes in the entorhinal cortex, a key re-
gion of the brain implicated early in the pathogenesis of AD
(Braak and Braak, 1991). Compared with previous studies of
transcriptional variation in TG mouse models of AD we profiled
a relatively large number of samples spanning multiple time
points selected to encompass the development of pathology;
our study was therefore well powered to identify gene expres-
sion differences associated with both genotype and the progres-
sion of AD pathology. Furthermore, we implemented a statistical
approach that enabled us to detect progressive changes in gene
expression across age between the TG and WT samples, not
only identifying stable differences induced by the transgene at
each time point but also assessing temporal transcriptional
changes relative to baseline within mutant mice. Our detailed
immunohistochemical analyses also allowed us to directly
compare transcriptional variationwith actual tau and amyloid pa-
thology quantified using immunohistochemistry in both the ento-
rhinal cortex and the hippocampus from the same individual
mice. We performed extensive work to validate key findings us-
ing qPCR, confirming pathology-associated changes in the en-
torhinal cortex and exploring the extent to which they are paral-
leled in matched hippocampus tissue dissected from the same
mice.
Despite these strengths, our study has a number of important
limitations that should be considered. First, to minimize the het-
erogeneity in our analysis, we profiled only female mice. How-
ever, a number of sex differences have been previously reported
for thesemodels, with females demonstrating elevated andmore
progressive pathology than males (Blackmore et al., 2017; Yue
et al., 2011). Future work should focus on examining the extent
to which the transcriptional profiles identified here are consistent
between male and female mice. Second, our analysis was per-
formed on bulk entorhinal cortex tissue, comprising a mix of
different neural cell types; consequently, changes in the frac-
tional contribution of any given cell type to the total cellular pop-
ulation will contribute to the observed outcomes at each time
point. Given the compelling evidence in our data for an enrich-
ment of microglial markers, previously shown to be upregulated
in AD (Hopperton et al., 2018; Keren-Shaul et al., 2017), as well
as upregulation of canonical markers of astrocytes (Figure S7),
futurework should focus on identifying changes that occur within
these and other brain cell types. Of note, immunocytochemistry
analyses of tissue sections from the left-brain hemisphere of
these mice revealed a progressive increase in the microglia/
macrophage marker Iba1, indicating that our bulk-tissue RNA-
seq measurements reflect real underlying cellular changes. In
rTg4510 mice it is also interesting to consider neuron-specific
genes that are not downregulated in what is a falling total
neuronal population; these might represent transcripts that are
actually upregulated in response to neuropathology in neuronal
cells. Third, compared with the rTg4510 model, relatively few
transcriptional changes were observed in J20 mice, potentially
reflecting the slower and later accumulation of pathology (Harris
et al., 2010b), as well as the potential absence of neurodegener-
ation, in the entorhinal cortex in this model. This is confirmed by
our immunohistochemistry data, which revealed much lower
amyloid pathology in the entorhinal cortex than hippocampus
tissue from the same J20 individuals (Figures 1E and 1F), and
by our targeted qPCR data on selected genes, which highlighted
stronger effects in the hippocampus than the entorhinal cortex
(Figure S8); future work should focus on more systematic tran-
scriptional profiling in other brain regions more directly affected
in the early stages of amyloid pathology. Interestingly, however,
we found that effect sizes for the transcripts identified as beingprogressively dysregulated in rTg4510 and J20mice were signif-
icantly correlated across bothmodels, suggesting common tran-
scriptional mechanisms involved in both tau and amyloid
pathology.
In summary, we observe widespread transcriptional changes
in the entorhinal cortex paralleling the progression of AD pathol-
ogy. Our data suggest that the altered expression of multiple
genes, including several known AD risk genes, is robustly asso-
ciated with the accumulation of tau, with tau-associated co-
expression networks overlapping those altered in human AD
cortex. Our data provide further support for an immune-
response component in the accumulation of tau and reveal
molecular pathways associated with the progression of AD
neuropathology.
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METHOD DETAILS
Brain samples
Mice were terminally anaesthetized with pentobarbital (intraperitoneal injection) and transcardially perfused with phosphate-
buffered saline (PBS), and their brains were collected. The entorhinal cortex and hippocampus were dissected from the left
brain hemisphere on wet ice (according to Heffner et al., 1980) and snap-frozen on dry ice for subsequent transcriptional analysis.
The right brain hemisphere was immersed in 10% buffered formalin for fixation (7-8 days) and processed for subsequent
immunohistochemistry pathology assessments.
Histopathology
The right hemisphere from all animals was processed using a Tissue TEK VIP processor (GMI Inc) and embedded in paraffin wax.
6 mm serial sagittal sections (from bregma 0.84 to 3.00) were obtained using rotary microtomes (HM 200 from Ergostar and HM 355S
from Thermo Scientific), with sections mounted on glass slides (two sections per slide). Negative and positive controls were used fore2 Cell Reports 30, 2040–2054.e1–e5, February 11, 2020
each immunohistochemistry experiment. Deparaffinisation of the tissue was achieved using xylene (Fisher Scientific), followed by
70% ethanol (industrial methylated spirit, Fisher Scientific) and deionised water for rehydration of the sections. Heat induced epitope
retrieval was performed in a PT Module (Thermo Scientific) containing citrate buffer (dilution 1:100). Samples were blocked using
normal goat serum (Vector labs, catalog number S-1000). To assess tau pathology, we used mouse monoclonal PG5 (provided
by Peter Davies from Albert Einstein College of Medicine, Bronx, NY, USA) (Jicha et al., 1999) as the primary antibody (1:8000), which
recognizes tau phosphorylated at Ser409, and biotinylated goat anti-mouse IgG (Vector labs, catalog number BA-9200, lot number
2B0324) as the secondary antibody (1:200), as previously described (Ahmed et al., 2014). Using this same protocol, we also assessed
tau pathology with the mouse monoclonal AT8 (provided by Eli Lilly, 1:4000) primary antibody specific for tau phosphorylated at
Ser202 and Thr205. To assess amyloid pathology, we used mouse monoclonal biotinylated 3D6 (b3D6, provided by Eli Lilly,
1:1000), which binds to the amino acids 1-5 in amyloid beta (Ab) (Demattos et al., 2012). To quantify Iba1, we used rabbit polyclonal
anti-Iba1 (Wako, catalog number 019-19741, lot number LKG5732) as the primary antibody (diluted 1:6000), and biotinylated
goat anti-rabbit IgG (Vector labs, catalog number BA-1000, lot number ZB1007) as the secondary antibody (diluted 1:200). All
samples for each mouse model were immunostained together in an autostainer (Autostainer 720 for PG-5 and 720N for
b3D6, Thermo Scientific). For detection we undertook enzymatic labeling using peroxidase (Vectastain Elite ABC HRP Reagent,
Vector Laboratories) and DAB substrate (Vector Laboratories). Images were digitised with Scanscope AT slide scanner (Aperio) at
20x magnification. Visualization of the digitized tissue sections and delineation of the regions of interest (hippocampus, cortex,
thalamus and entorhinal cortex) were achieved using Imagescope software (version 12.2.1.5005; Aperio). Positivity was quantified
automatically using a positive pixel algorithm calibrated to ignore non-specific staining, and the burden of tau or amyloid pathology
was expressed as percentage area. Statistical analysis (two-way ANOVA) was performed using R (version 3.4.3).
RNA isolation and highly-parallel RNA sequencing
Samples were labeled with anonymized ID codes and processed in batches, blinding genotype from the experimenter/analyst for
individual samples. Tissue samples from each model were processed separately and individual samples were randomized to ensure
that each group was equally represented in each processing batch. Total RNA from the entorhinal cortex and hippocampus was iso-
lated using the AllPrep DNA/RNA Mini Kit (QIAGEN), with minor modifications to the manufacturer’s protocol. Briefly, we added
lysis buffer (containing added b-mercaptoethanol) to each tissue sample, disrupted the tissue using a homogenizing pestle, and ho-
mogenized the lysate using a pipette. The lysate was centrifuged and the supernatant removed and transferred to an AllPrep DNA
spin column. After centrifugation, the flow-through was used for RNA purification by mixing with 70% ethanol, running it through the
RNeasy spin column (including DNase treatment) and eluting in RNase-free water. RNA quality and quantity for all samples was
checked using RNA ScreenTape (Agilent). The optimal eight entorhinal cortex samples for each group (RIN R 8, Tables S1 and
S2) were selected for transcriptional profiling (total n = 128 samples; two models (rTg4510/J20) x two groups (TG/WT) x four time-
points x eight individual animals per group). Stranded-specific mRNA sequencing libraries were prepared using the TruSeq Stranded
mRNA Sample Prep Kit (Illumina) using the Bravo Automated Liquid Handling Platform (Agilent). cDNA libraries were prepared from
450ng of total RNA plus ERCC spike-in synthetic RNA controls (Risso et al., 2014) (Ambion, dilution 1:100). Libraries were individ-
ually cleaned up using Ampure XP magnetic beads (Beckman Coulter), their concentrations were determined using D1000 Screen-
Tape System (Agilent), and samples were pooled together to a 2nM concentration, for subsequent sequencing (three pools of 22
samples for J20 samples and one pool of 64 samples for rTg4510 samples). Pooled libraries were quantified using a Qubit Fluorom-
eter (Thermo Fisher Scientific), Tapestation HS ScreenTape System (Agilent Technologies), and qPCR. Final library pools were
distributed across twelve HiSeq2500 (Illumina) lanes (six lanes for each model) and subjected to 125bp paired-end sequencing
yielding a mean untrimmed read depth of 20 million reads/sample (Tables S1 and S2).
Validation of specific gene expression differences using qPCR
Total RNA isolated from the entorhinal cortex and the hippocampus (n = 7-8 animals per group) was used for targeted gene expres-
sion analysis. Complementary DNA (cDNA) was reverse transcribed using the EvoScript Universal cDNA Master (Roche) and quan-
titative RT-PCR was performed in duplicate using the QuantStudio 12 K Flex (Applied Biosystems) using TaqMan low-density arrays
(TLDA) and preoptimized assays targeting (i) the top-ranked genotype-associated DEGs in each mouse model (Car4, Gpr17, Blnk,
Hspa5, Ccdc80, Abca8a, and Htr1a), (ii) selected top-ranked interaction (Genotype*Age)-associated DEGs (Gfap, Cd68, Itgax,
Clec7a, and Cst7), (iii) genes previously implicated in AD pathology from genetic studies in humans and found to progressively
change in our rTg4510 RNA-seq dataset (Trem2, Pld3, Frmd4a, Clu, Apoe, Picalm, and Cd33), (iv) three housekeeping genes
(Actb, Eif4a2, and Gapdh), and (v) one internal control (18S ribosomal RNA). The full list of qPCR assays used is described in the
Key Resources Table.
QUANTIFICATION AND STATISTICAL ANALYSIS
RNA-seq data processing
All sequencing data processing was performed on a Unix-based operating system server at the University of Exeter. Raw files were
demultiplexed into FASTQ files (Phred (Q)R 35, Tables S1 and S2) and checked for potential contamination. The randomized FASTQ
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removal, quality threshold 20, minimum sequence length 35) was performed with fastqmcf. (Aronesty, 2011) (version 1.0) and
trimmed samples were aligned to the mm10 (GRCm38.p4) reference mouse genome using STAR (Dobin et al., 2013) (version
2.5.3a), with mappingR 85% (Tables S1 and S2). Gene expression quantification (quantification of fragments or templates, hereby
referred as read counts) was achieved using featureCounts (Liao et al., 2014) (version 1.5.2). Following confirmation of genotype and
QC, 7 samples were excluded from subsequent analysis leaving a final number of 121 high-quality RNA-seq datasets (6-8 animals
per group).
RNA-seq gene expression analysis
All analyses were performed in R (version 3.4.3) unless otherwise stated. Read counts were analyzed for differential expression using
the R package DESeq2 (Love et al., 2014) (version 1.16.1) downloaded fromBioconductor (Matarin et al., 2015). DESeq2 uses the raw
read counts, applies an internal normalization method, and does estimation of library size, estimation of dispersion, and negative
binomial generalized linear model fitting (Love et al., 2014). Datasets were filtered for non-expressed and lowly expressed genes
(minimum of 6 counts across all samples). We were interested in detecting both genotype effects and progressive changes across
age between the transgenic andwild-type samples.We used the following statistical model, includingmain effects for bothGenotype
and Age (both coded as categorical variables) and an interaction between these two terms:
Gene expression = Genotype+Age+Genotype  Age
To identify significant genotype effects a Wald test was used, and to identify significant effects of age and interaction effects (i.e.,
Genotype*Age) we used the likelihood-ratio test, both applied with the DESeq function from the DESeq2 package (Love et al., 2014).
To test for associations between gene expression and measures of neuropathology quantified using immunohistochemistry, we
fitted linear models usingDESeq and used aWald test to calculate P values. Thesemodels were fitted separately for neuropathology
data measured in the entorhinal cortex and hippocampus for each individual. P values were adjusted for multiple testing using the
false discovery rate (FDR) method (also known as Benjamini and Hochberg correction) (Benjamini and Hochberg, 1995) implemented
with the R function p.adjust; FDR values < 0.05 were defined as significant. Potential differences in proportions of upregulated versus
downregulated genes as well as overlapping fold changes in bothmodels were interrogated using the binomial test. Functional anno-
tation and gene ontology analyses were done with GOseq (Young et al., 2010) (1.30.0), based on genes with FDR < 0.05.
Quantifying human transgene expression
Mouse and human App/APP and Mapt/MAPT sequences were compared using BLAT (Kent, 2002) for divergent transcript
sequences representing specific mouse and human gene sequences. Two 200bp regions spanning 4 exons were chosen as repre-
sentativemouse-specificApp. Similar regions consisting of two 200bp exonic regions were also chosen for humanAPP. Mouse-spe-
cific Mapt and human-specific MAPT sequences were chosen from a 2kb region present in the 30UTR. Using Bowtie2 (Langmead
et al., 2009) (version 2.3.4.3), indices based on these sequences were then built, and alignments were performed using the FASTQ
read 1 sequences. Counts of read alignments for mouse and human specific indices were then plotted as a ratio of unique (mouse or
human) reads relative to the total number of input reads.
Comparison with RNA-seq data from the Mouseac database
RNA-seq data (transcripts per million, TPM) from two mouse models (Matarin et al., 2015; Salih et al., 2019) (TAU (CaMKII-
MAPTP301L) and TAS10 (SwAPP, K670N/M671L)) were downloaded from the Mouseac online database (www.mouseac.org),
with corresponding detailed phenotypic data downloaded from GEO (Barrett et al., 2013; Edgar et al., 2002) (accession number
GSE64398). Only genes identified as differentially expressed (FDR < 0.05) in our analysis (for rTg4510 and J20 mice) were selected
for further statistical analysis. The TPM value for each gene was log transformed (log2(x+1)) and the same linear regression model
described above (Gene expression = Genotype + Age + Genotype  Age), using ANOVA to test for significant differences associ-
ated with either the Genotype, Age, or Genotype*Age terms, was used. P values were corrected for the number of genes compared
across datasets using Bonferroni correction. Potential differences in proportions of upregulated versus downregulated genes as well
as overlapping fold changes in both models were interrogated using the binomial test.
Co-expression network analysis
Using weighted co-expression network analysis (Langfelder and Horvath, 2008; Zhang and Horvath, 2005) (WGCNA) (version 1.63),
we constructed a signed co-expression network for each mouse model using log transformed counts from all samples. Logarithmic
transformation of raw counts was achieved using the rlog function fromDESeq2, whichminimizes variability in genes with low counts
(Love et al., 2014). We checked the data for missing values and outliers, and removed one sample from the analysis for the rTg4510
dataset (flagged as an outlier) before building the networks. Signed WGCNA co-expression networks were built using the lowest
power for which the scale-free topology fit index curve flattened out after reaching 0.90 resulting in a soft-threshold power of 10
and 9 for rTg4510 and J20 datasets, respectively, and aminimummodule size of 30. For eachmodule of highly interconnected genes,
color-labeled according to theWGCNA conventions, we calculated the module eigengenes (MEs) as the first principal component of
the expression matrix, which provide a representative expression profile for each module (Langfelder and Horvath, 2008). In order
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with the available pathology data and explored the most significant associations. In addition we used the same linear regression
model as described for the gene-level analysis (ME = Genotype + Age + Genotype  Age) using ANOVA to test for significant dif-
ferences due to either the Genotype, Age, or Genotype*Age terms. P values were corrected for multiple comparisons using the Bon-
ferroni correction, to correct for 18 modules in the rTg4510 (statistical threshold was adjusted to 0.05/18 = 0.0028) and 21modules in
the J20 (statistical threshold was adjusted to 0.05/21 = 0.0024)mice.We used theGOseqRpackage (version 1.30.0) to perform func-
tional annotation and gene ontology (GO) analyses for each module, where significant pathways were selected using an FDR
threshold of 0.05 as previously described (Young et al., 2010). We used Cytoscape (Shannon et al., 2003) (version 3.7.0) for network
visualization using the topological overlap matrix for the log transformed expression data.
Comparison with human co-expression networks
The six rTg4510-associated co-expression modules identified in this study (‘‘salmon,’’ ‘‘turquoise,’’ ‘‘purple,’’ ‘‘yellow,’’ ‘‘light-cyan,’’
and ‘‘red’’), and AD-associated human co-expression modules in the dorsolateral prefrontal cortex (DLPFC) and temporal cortex
(TCX) (Logsdon et al., 2019), were reduced to contain only mouse-human homologs as defined by Ensembl (Zerbino et al., 2018)
(accessed on 14/11/2018). The level of overlap between gene members of each pair of modules was assessed via a hypergeometric
test using the R (version 3.5.1) function phyper. P values were corrected for multiple comparisons using Bonferroni correction in a
tissue-specific manner, where only the set of raw P values related to DLPFC (statistical threshold was adjusted to 0.05/24 =
0.0021) or TCX (statistical threshold was adjusted to 0.05/30 = 0.0017) modules’ overlap were considered. Using GOseq (version
1.30.0), we performed functional annotation and GO analyses for the common genes in each overlapping pair of modules.
Targeted qPCR analysis
The abundance of each test gene was determined using the comparative Ct method (Pfaffl, 2001), expressed relative to the mean of
the three housekeeping genes selected using RefFinder software (Xie et al., 2012) that determines the best stably expressed refer-
ence gene(s). A linear regression model using ANOVA to test for significant differences associated with either Genotype, Age, or
Genotype*Age terms was used (DCt = Genotype + Age + Genotype  Age), with P values adjusted for multiple testing using the
FDR method implemented with the R function p.adjust.
DATA AND CODE AVAILABILITY
Raw RNA-seq data has been deposited in GEO under accession number GSE125957. Results for all expressed transcripts in both
transgenic models are available to download from www.epigenomicslab.com/ADmice. The code supporting the current study is
available at https://git.exeter.ac.uk:443/ic322/ad-mice-rna-seq-cell-reports.Cell Reports 30, 2040–2054.e1–e5, February 11, 2020 e5
